SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
BiotechTV - News
00:00
Mechanism: immunostabilizer versus blocker
Marc describes obefazimod as an immunostabilizer with efficacy across patients and a favorable safety profile.
Play episode from 07:25
Transcript
